Open AccessCurrent and emerging treatments for amyotrophic lateral sclerosis
Author(s) -
Zoccolella
Publication year - 2009
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.819
H-Index - 67
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s7788
Subject(s) - riluzole , amyotrophic lateral sclerosis , medicine , clinical trial , quality of life (healthcare) , disease , drug , medline , food and drug administration , intensive care medicine , pharmacology , nursing , political science , law
Amyotrophic lateral sclerosis (ALS) is a relatively rare neurodegenerative disorder of both upper and lower motoneurons. Currently, the management of ALS is essentially symptoms-based, and riluzole, an antiglutamatergic agent, is the only drug for the treatment of ALS approved by the food and drug administration.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom